Effect of PEX, a noncatalytic metalloproteinase fragment with integrin-binding activity, on experimental

Dario Caronzolo1, Valeria Lucini, Marilou Pannacci

  • 1Department of Pharmacology, Chemotherapy, and Toxicology, University of Milan, Milan, Italy. francesco.scaglione@unimi.it

Insights

PEX effectively treats Chlamydophila pneumoniae infections by targeting alpha(v)beta(3) integrin. This pathogen is linked to respiratory issues and heart disease, making PEX a potential new therapeutic strategy.

Area of Science:

  • Microbiology
  • Immunology
  • Pharmacology

Background:

  • Chlamydophila pneumoniae is a significant pathogen implicated in acute and chronic respiratory infections.
  • This bacterium is also associated with the development of asthma and coronary artery diseases.
  • Understanding the pathogen's interaction with host cell receptors is crucial for developing effective treatments.

Purpose of the Study:

  • To evaluate the efficacy of PEX, a metalloproteinase fragment, against experimental Chlamydophila pneumoniae infections.
  • To investigate the role of alpha(v)beta(3) integrin in C. pneumoniae infection.
  • To elucidate the mechanism of action of PEX in vitro and in vivo.

Main Methods:

  • In vitro experiments involved infecting HeLa cells with C. pneumoniae and treating with PEX or azithromycin.
  • In vivo studies utilized a mouse lung infection model, treating intranasally inoculated mice with PEX or antibiotics.
  • Cell susceptibility assays were performed using cells expressing alpha(v)beta(3) integrin.

Main Results:

  • PEX demonstrated comparable efficacy to azithromycin in vitro and in vivo models of C. pneumoniae infection.
  • Treatment with PEX significantly reduced C. pneumoniae counts in infected mice.
  • Alpha(v)beta(3) integrin plays a critical role in C. pneumoniae infection, with blockage inhibiting pathogen entry.
  • Cells overexpressing alpha(v)beta(3) integrin were significantly more susceptible to infection.

Conclusions:

  • PEX is a promising agent for treating Chlamydophila pneumoniae infections.
  • Alpha(v)beta(3) integrin represents a viable therapeutic target for novel anti-C. pneumoniae agents.
  • These findings open new avenues for managing infections caused by this pathogen.

Related Concept Videos

Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Bacterial Phylum Chlamydiae01:29

Bacterial Phylum Chlamydiae

The phylum Chlamydiae or Chlamydiota is composed of a single order, Chlamydiales. This phylum consists entirely of obligate intracellular parasites that infect eukaryotic hosts. While human pathogens within this group have been studied extensively, the phylum encompasses many species capable of interacting with various eukaryotic organisms. Members of Chlamydiae are typically small cocci, approximately 0.5 μm in diameter, and exhibit a distinctive developmental cycle. As is characteristic of...
Activation of Integrins01:15

Activation of Integrins

Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.